News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,438 signal articles · 141 in last 24h · 154,019 total before filter · latest 27m ago

141last 24h

874last 7d

144● bullish (7d)

99● bearish (7d)

214publishers

All Macro208 Earnings106 M&A125 Regulatory22 Product21 Analyst16

✕ clear all filtersticker: TEMSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Simply Wall St.5d agoneutral

Tempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million Genomes

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

TEM

Insider Monkey80d agoneutral

Tempus AI (TEM) Launches Next-Gen Agentic Platform to Accelerate Oncology Research

Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug development. By integrating Tempus’ massive library of longitudinal real-world data, oncology foundation models, and computational infrastructure, the platform provides an […]

TEM

Insider Monkey123d agoneutral

Tempus AI (TEM) Launches ArteraAI Prostate Test, The First Externally Developed Digital Pathology Algorithm

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector. In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made two announcements that add to its growing pipeline of clinical and pharma partnerships. The freshest update came […]

TEM